Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO)
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This study is a multicentre, double-blinded, randomized, placebo-controlled, clinical trial
with open-label extension.
The purpose and aim of this study is to investigate the efficacy and safety of roflumilast
(PDE4-inhibitor) in adult patients with chronic hand eczema (CHE).
Patients will receive 16-week treatment with either roflumilast or placebo tablets.
Hereafter, both groups continue in open-label treatment for 12 weeks where both groups will
receive treatment with roflumilast.